<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04869813</url>
  </required_header>
  <id_info>
    <org_study_id>21-124</org_study_id>
    <nct_id>NCT04869813</nct_id>
  </id_info>
  <brief_title>Sarcopenia Magnetic Resonance Imaging Evaluation (SUSIE)</brief_title>
  <acronym>SUSIE</acronym>
  <official_title>Sarcopenia Characterization Using Magnetic Resonance Fingerprinting and Phosphorous Magnetic Resonance Spectroscopic Imaging Evaluation (SUSIE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of the proposed research is to investigate Magnetic Resonance (MR) Fingerprinting&#xD;
      and P-MRS (Phosphorus-31 MR Spectroscopy) imaging for characterization of skeletal muscle in&#xD;
      heart failure patients with sarcopenia. Heart failure patients with and without sarcopenia&#xD;
      will be scanned using MR Fingerprinting and an existing Post-exercise phosphocreatine (PCr)&#xD;
      recovery MR imaging protocol to obtain characteristic profiles of quantitative T1, T2, and&#xD;
      PCr recovery rate.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sarcopenia is a common comorbidity and predictor of mortality in heart failure that is&#xD;
      characterized by a loss of muscle mass and functional strength. Sarcopenia, in heart failure&#xD;
      and other chronic diseases, has been consistently predictive of poor outcomes. However,&#xD;
      current tools to identify the presence of sarcopenia, such as functional tests and&#xD;
      questionnaires are indirect, non-specific, and not effective until patients have reached an&#xD;
      overtly cachectic state and significant muscle deterioration has already occurred. MRI can&#xD;
      serve an important, noninvasive role in the assessment and management of sarcopenia by&#xD;
      providing insight as to tissue microstructure and mitochondrial function. For example, MRI&#xD;
      has shown significant changes in T2 relaxation time, diffusion fractional anisotropy, and&#xD;
      lipid content in skeletal muscle of pre-frail/frail patients as compared to healthy&#xD;
      volunteers. Post-exercise phosphocreatine (PCr) recovery, evaluated using phosphorus-31 (P)&#xD;
      MR spectroscopy Imaging(P-MRSI), has shown impairment of mitochondrial function in pre-frail&#xD;
      elderly as compared to active elderly. MR fingerprinting (MRF) is a promising tool for tissue&#xD;
      characterization via rapid, robust quantification of T1 and T2 relaxation and has been shown&#xD;
      to be accurate and reproducible across sites. Despite applications in neuroimaging and&#xD;
      cardiac imaging, MRF has had limited use in musculoskeletal imaging and has not been&#xD;
      investigated for use in characterizing sarcopenia. Similarly, P-MRS imaging has not been&#xD;
      employed for evaluation of sarcopenia in heart failure patients, a population which may have&#xD;
      a unique etiology from other sarcopenia phenotypes. Characterization of sarcopenia may&#xD;
      support a range of rapidly developing treatment options in this population. While evidence&#xD;
      suggests exercise therapy can improve frailty status, for instance in 39% of patients at 12&#xD;
      month follow-up, it is not yet well-understood which patients will respond to treatment. With&#xD;
      a range of treatment options such as nutritional supplementation, hormone therapy, and&#xD;
      cardiovascular drugs, MRF and P-MRSI could serve as powerful noninvasive tools to provide a&#xD;
      personalized approach for sarcopenic phenotypes, match them to appropriate therapy, and&#xD;
      monitor therapeutic response.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 9, 2021</start_date>
  <completion_date type="Anticipated">April 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Anticipated Results</measure>
    <time_frame>3 years</time_frame>
    <description>This proposal is expected to produce information as to the change in T1, T2, muscle area, fat fraction, and PCr recovery rate values for heart failure patients with sarcopenia as compared to non-sarcopenic volunteers. Future work will expand upon this study to evaluate to progression of sarcopenia, and evaluate the prognostic value of imaging biomarkers (T1, T2, muscle area, fat fraction, PCr recovery) in predicting heart failure and sarcopenic related outcomes.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Sarcopenia</condition>
  <arm_group>
    <arm_group_label>Heart failure patients</arm_group_label>
    <description>Inclusion criteria:&#xD;
Age &gt; or = 40 yrs&#xD;
Stable chronic heart failure&#xD;
Systolic dysfunction determined by cardiac MRI with left ventricle ejection fraction 40% or less&#xD;
Exclusion criteria:&#xD;
• Advanced liver disease, advanced cancer, advanced chronic obstructive pulmonary disease&#xD;
Contraindications to MRI such as:&#xD;
Heart pacemaker/defibrillator&#xD;
Electronic/implanted stimulators or devices, including deep brain stimulator, vagus nerve stimulator, bladder stimulator, spine stimulator, neurostimulators; implanted electrodes or wires&#xD;
Cochlear implant or other ear implants&#xD;
Implanted drug pumps (insulin, narcotic/pain medications, drugs to treat spasticity)&#xD;
Programmable shunt&#xD;
Aneurysm clips and coils&#xD;
Stents • Filters (for example, blood clot filters)&#xD;
Metal fragment in body or eye (eg, BBs, bullets, shrapnel, metal pieces or shavings)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy volunteers (Controls)</arm_group_label>
    <description>Inclusion criteria:&#xD;
Age &gt; or = 40 yrs&#xD;
No diagnosed heart failure or sarcopenia&#xD;
Exclusion criteria&#xD;
• Advanced liver disease, advanced cancer, advanced chronic obstructive pulmonary disease&#xD;
Contraindications to MRI such as:&#xD;
Heart pacemaker/defibrillator&#xD;
Electronic/implanted stimulators or devices, including deep brain stimulator, vagus nerve stimulator, bladder stimulator, spine stimulator, neurostimulators; implanted electrodes or wires&#xD;
Cochlear implant or other ear implants&#xD;
Implanted drug pumps (insulin, narcotic/pain medications, drugs to treat spasticity)&#xD;
Programmable shunt&#xD;
Aneurysm clips and coils&#xD;
Stents • Filters (for example, blood clot filters)&#xD;
Metal fragment in body or eye (eg, BBs, bullets, shrapnel, metal pieces or shavings)</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood and urine&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Heart Failure and Healthy volunteers&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Heart failure patients&#xD;
&#xD;
               -  Age ≥40 yrs&#xD;
&#xD;
               -  Stable chronic heart failure&#xD;
&#xD;
               -  Systolic dysfunction determined by cardiac MRI with left ventricle ejection&#xD;
                  fraction 40% or less&#xD;
&#xD;
          -  Healthy Volunteers&#xD;
&#xD;
               -  Age ≥40 yrs&#xD;
&#xD;
               -  No diagnosed heart failure or sarcopenia&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Heart failure patients&#xD;
&#xD;
             • Advanced liver disease, advanced cancer, advanced chronic obstructive pulmonary&#xD;
             disease&#xD;
&#xD;
          -  Healthy volunteers (controls)&#xD;
&#xD;
               -  Advanced liver disease, advanced cancer, advanced chronic obstructive pulmonary&#xD;
                  disease&#xD;
&#xD;
               -  Contraindications to MRI Contraindications to MRI&#xD;
&#xD;
               -  Heart pacemaker/defibrillator&#xD;
&#xD;
               -  Electronic/implanted stimulators or devices, including deep brain stimulator,&#xD;
                  vagus nerve stimulator, bladder stimulator, spine stimulator, neurostimulators;&#xD;
                  implanted electrodes or wires&#xD;
&#xD;
               -  Cochlear implant or other ear implants&#xD;
&#xD;
               -  Implanted drug pumps (insulin, narcotic/pain medications, drugs to treat&#xD;
                  spasticity)&#xD;
&#xD;
               -  Programmable shunt&#xD;
&#xD;
               -  Aneurysm clips and coils&#xD;
&#xD;
               -  Stents&#xD;
&#xD;
               -  Filters (for example, blood clot filters)&#xD;
&#xD;
               -  Metal fragment in body or eye (eg, BBs, bullets, shrapnel, metal pieces or&#xD;
                  shavings)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>W. H. Wilson Tang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Timothy A Engelman, LPN</last_name>
    <phone>216-636-6153</phone>
    <email>engelmt@ccf.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wilcox D Wilcox, BA</last_name>
    <phone>216-636-6153</phone>
    <email>kirsopj@ccf.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tim Engelman, LPN</last_name>
      <phone>216-636-6153</phone>
      <email>engelmt@ccf.org</email>
    </contact>
    <contact_backup>
      <last_name>Jen Wilcox, BA</last_name>
      <phone>216-636-6153</phone>
      <email>kirsopj@ccf.org</email>
    </contact_backup>
    <investigator>
      <last_name>Brendan Eck, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 28, 2021</study_first_submitted>
  <study_first_submitted_qc>April 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 3, 2021</study_first_posted>
  <last_update_submitted>April 28, 2021</last_update_submitted>
  <last_update_submitted_qc>April 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Cleveland Clinic</investigator_affiliation>
    <investigator_full_name>Wilson Tang</investigator_full_name>
    <investigator_title>Staff Cardiovascular and Metabolic Sciences</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcopenia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

